Nicholas von Guionneau is a Principal at Catalio Capital Management, where he makes private credit and venture investments in innovative healthcare companies. He specializes in breakthrough medtech and neurotherapeutics. Nicholas represents Catalio on the Board of Proto Axiom and serves as a Board Observer on numerous investments including Amalgam Rx, Centrexion, Character Biosciences, Leo Cancer Care, Orasis Pharmaceuticals, Ospri, SetPoint Medical, and Syndeio Biosciences.
Prior to Catalio, Nicholas was a Postdoctoral Research Fellow at Johns Hopkins Medicine, focused on peripheral nerve regeneration and developing implantable neurodevices, drug delivery systems, and small protein therapeutics. He began his career as a clinician at Guy’s and St. Thomas’ NHS Trust in London.
He holds an MBBS (Bachelor of Medicine, Bachelor of Surgery) and a BSc in Medical Sciences (Surgery and Anaesthesia) from Imperial College School of Medicine.